Flamingo Therapeutics Signed a Definitive Merger Agreement with Dynacure to Advance RNA-Targeted Oncology Therapies
- The combined company to be named Flamingo Therapeutics, focused on advancing Flamingo's danvatirsen in a P-II trial (PEMDA-HN) for Head & Neck cancer in combination with pembrolizumab where the planned 1EPs of the study is to determine the ORR & 2EPs will include safety, DoR, DCR, PFS & OS
- The combined company will also advance Flamingo's FTX-001, the most advanced long non-coding RNA (LncRNA) program targeting MALAT-1 for solid tumors
- The agreement uses common synergies of Flamingo and Dynacure, incl. deep expertise in RNA-targeting and clinical drug development. Danvatirsen is an antisense oligonucleotide (ASO) that targets STAT3 and has shown clinical activity in 2 P-II studies
Ref: Prnewswire | Image: Flamingo Therapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.